Gilead (GILD) Harvoni/Sovaldi Label Changes Are Not Meaningful, Baird Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Gilead (GILD) Weakness Following HCV Warning Seen as Potential Buying Opportunity
March 23, 2015 6:41 AM EDTWells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $123-$127. Analyst Brian Abrahams commented on a... More
iShares Nasdaq Biotechnology (IBB) Poised to Open Up Over 2%
March 20, 2015 8:11 AM EDTiShares Nasdaq Biotechnology (NASDAQ: IBB) is poised to open higher by over 2%. Top holdings in the ETF are Biogen Idec (NASDAQ: BIIB), Celgene (NASDAQ: CELG), Gilead Sciences (NASDAQ: GILD), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN).
